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Abstract
Background: Conflicting research has identified METCAM/MUC18, an integral membrane cell adhesion molecule
(CAM) in the Ig-like gene super-family, as both a tumor promoter and a tumor suppressor in the development of
breast cancer. To resolve this, we have re-investigated the role of this CAM in the progression of human breast
cancer cells.
Methods: Three breast cancer cell lines were used for the tests: one luminal-like breast cancer cell line, MCF7,
which did not express any METCAM/MUC18, and two basal-like breast cancer cell lines, MDA-MB-231 and MDA-
MB-468, which expressed moderate levels of the protein.
MCF7 cells were transfected with the human METCAM/MUC18 cDNA to obtain G418-resistant clones which
expressed the protein and were used for testing effects of human METCAM/MUC18 expression on in vitro motility
and invasiveness, and in vitro and in vivo tumorigenesis. Both MDA-MB-231 and MDA-MB-468 cells already
expressed METCAM/MUC18. They were directly used for in vitro tests in the presence and absence of an anti-
METCAM/MUC18 antibody.
Results: In MCF7 cells, enforced METCAM/MUC18 expression increased in vitro motility, invasiveness, anchorage-
independent colony formation (in vitro tumorigenesis), and in vivo tumorigenesis. In both MDA-MB-231 and MDA-
MB-468 cells, the anti-METCAM/MUC18 antibody inhibited both motility and invasiveness. Though both MDA-MB-
231 and MDA-MB-468 cells established a disorganized growth in 3D basement membrane culture assay, the
introduction of the anti-METCAM/MUC18 antibody completely destroyed their growth in the 3D culture.
Conclusion: These findings support the notion that human METCAM/MUC18 expression promotes the progression
of human breast cancer cells by increasing their motility, invasiveness and tumorigenesis.
Background
METCAM (alternative names as MUC18, CD146,
S-endo 1, MelCAM, and MCAM), an integral mem-
brane cell adhesion molecule (CAM) in the Ig-like gene
super-family, has an immunoglobulin-like extra-cellular
domain and a cytoplasmic domain, which contains five
consensus sequences potentially phosphorylated by
PKA, PKC, and CK2 [1,2]. Thus METCAM/MUC18 is
capable of performing the typical functions of CAMs:
adhesion (cell-cell and cell-extracellular matrix interac-
tions), response to extra-cellular stimuli, intra-cellular
interactions with cytoskeleton, and cross-talk with sig-
naling pathways. In addition, METCAM/MUC18 may
regulate tumor dormancy, drive cancer cells to a pre-
metastatic niche, and help provide a microenvironment
for tumor growth in secondary sites [3-5]. The altered
expression of METCAM/MUC18 has been shown to
increase cell motility, invasiveness, metastasis, and/or
tumorigenesis in a number of cancers, including mela-
noma and prostate cancer [3,4,6-10]. However, the role
of METCAM/MUC18 in the progression of human
breast cancer cells has been controversial. Results from
two groups appeared to support the notion that MET-
CAM/MUC18 may be a tumor suppressor [11,12]. For
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expression of METCAM/MUC18 suppressed the tumor
growth of breast cancer MCF7 cells in SCID mice [11].
In addition, Ouhtit et al. [12] recently showed that
enforced expression of METCAM/MUC18 in the MDA-
MB-231 breast cancer cell line decreased in vitro inva-
siveness. On the other hand, results of two other groups
appeared to support the opposite notion that MET-
CAM/MUC18 may play a positive role in the progres-
sion of breast cancer [13,14]. Garcia et al.s h o w e dt h a t
increased expression of METCAM/MUC18 was corre-
lated with a poor prognosis in breast carcinoma, sug-
gesting a positive correlation of METCAM/MUC18
expression with breast carcinoma progression [13].
Zabouo et al. showed that METCAM/MUC18 is
expressed in a subset of epithelial cells in malignant
breast cancer and that it may contribute to tumor
aggressiveness by promoting malignant cell motility
(anti-METCAM/MUC18 antibodies decreased motility
of MDA-MB-231 cells and transmigration of the same
cells through established human endothelial cell layers
and reduced the ability of the cells in healing a wound)
[14]. These results are more consistent with the cur-
rently well-established positive role of METCAM/
MUC18 in the progression of melanoma, prostate can-
cer, and osteosarcomas [3] and also with the promotion
in tumor angiogenesis in tumors [15]. Taken together,
more evidence appears to favor the notion that the
M E T C A M / M U C 1 8e x p r e s s i o np l a y sap o s i t i v er o l ei n
the progression of breast cancer cells.
In this report, we reinvestigated the role of METCAM/
MUC18 in the progression of breast carcinomas. First,
we determined the expression of METCAM/MUC18 in a
luminal breast cancer cell line, MCF7, which was used by
S h i he ta l[ 1 1 ] .F u r t h e r m o r e ,w ea l s oe x p a n d e do u r
experiment to include another luminal cell line, SK-BR-3
[16,17]. Similar to Shih et al [11] we transfected MCF7
cells with the human METCAM/MUC18 (huMETCAM/
MUC18) cDNA gene and obtained many G418-resistant
(G418
R) clones for testing the effect of enforced expres-
sion of the protein on in vitro motility, invasiveness, and
anchorage-independent colony growth in soft agar. Using
the same MCF7 clones, we carried out additional experi-
ments to determine the effects of METCAM/MUC18
expression on in vivo tumorigenesis in SCID mice. We
also determined the effect of METCAM/MUC18 in a
basal cell-like breast cancer cell line, MDA-MB-231,
which was used by Ouhtit et al. [12] and Zabouo et al.
[14]. Again, we expanded our experiment to include an
additional basal cell-like cell line, MDA-MB-468 [16,17].
Furthermore, we tested the effects of an anti-human-
METCAM/MUC18 antibody on in vitro motility, inva-
siveness, and a disorganized growth in a 3D basement
membrane culture assay of MDA-MB-231 and MDA-
MB-468 cells. From our results, we have presented evi-
d e n c et os u p p o r tt h en o t i o nt h a tt h eM E T C A M / M U C 1 8
expression plays a positive role in the progression of
human breast cancer cells.
Methods
Cell lines
Human breast cancer cell lines MCF7, SK-BR-3, MDA-
MB-231 and 468 were from ATCC. Media were from
Invitrogen/Life Technology/GIBCO/BRL. MCF7 cells
were maintained in the EMEM medium containing 10%
fetal bovine serum (FBS) (Cellgro/MediaTech) and 10
μg/ml of bovine insulin (Sigma/Aldrich). SK-BR-3 cells
were maintained in the McCoy’s 5A medium supple-
mented with 10% FBS. MDA-MB-231 and MDA-
MB-468 cells were maintained in the Leibovitz’sL - 1 5
medium supplemented with 10% FBS. SK-Mel-28 and
DU145 cells from ATCC were maintained in the EMEM
medium containing 10 mM of Na-pyruvate and 10%
FBS. LNCaP cells from ATCC were maintained in a
modified RPMI1640 medium supplemented with
25 mM HEPES buffer, 1 mM Na.pyruvate, 1 mM gluta-
mine, 4.5% glucose and 10% FBS. All G418-resistant
(G418
R) MCF7 clones were grown in the same medium
of parental MCF7 cells plus 0.5-1 mg/ml G418 (Cellgro/
MediaTech and Hyclone). All cell lines and MCF7
clones/cells were maintained in a humidified 37°C incu-
bator with 5% CO2 except that MDA-MB-231 and
MDA-MB-468 cell lines were maintained in a humidi-
fied 37°C incubator without CO2.
Lipofection of MCF7 cells and selection for METCAM/
MUC18-expressing G418
R-clones
6×1 0
5 of MCF7 cells were seeded on 60 mm tissue
culture Petri dish plates to give about 50% confluence.
After one day of growth, monolayer cells were trans-
fected with a mixture of 30 μg of DEMRIE-C (Invitro-
gen/Life Technology), or FuGene HD (Roche), and 5 μg
of the huMETCAM/MUC18 cDNA gene in the plasmid
pcDNA3.1+, which contained a HCMV-IE promoter-
driven huMETCAM/MUC18 cDNA gene and a SV40
promoter-driven neomycin-resistant gene. 0.5-1 mg/ml
of G418 (active component about 72%) was added to
the growth medium after transfection and G418
R-clones
emerged in about two weeks. Clones were transferred
and expanded sequentially from 24-well to 12-well, then
to 6-well culture plates. Cell lysate of each clone was
made by adding100 μl of Western blot lysis buffer to
the culture in each well of 6-well plates [18], which
were then boiled and kept frozen at -20 C until Western
blot analysis [8,9]. The METCAM/MUC18-positive
clones in the duplicated 6-well plates were further
expanded to T-25 flasks and subsequently to T-75
flasks, then processed and frozen in liquid nitrogen for
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picked, the remaining colonies in the 60-mm plates
were trypsinized, mixed and seeded to two T-25 flasks;
cells grown in one flask were expanded, made stock,
and designated as a pooled clone; cells in another flask
were made into Western blot lysate and designated as a
pooled clone lysate.
Cell motility assay
A cell motility assay was carried out according to a pub-
lished method [19] with minor modifications [8,9]. 2 ×
10
5 cells of each clone/cell line in 0.4 ml of the growth
medium containing 0.1%-BSA were incubated with 7.5
to 15 μg/ml of a chicken anti-huMETCAM/MUC18
antibody [2,10] or the control isotype antibody (chicken
IgY) for 30 min and seeded to each top insert of the
polycarbonate membrane with a 8.0 μmp o r es i z e
(Fisher #08-771-12 or Falcon 35-3182) that fits into bot-
tom wells of a companion 12-well plate of the Boyden
type Transwell system (Fisher #08-771-22 or Falcon
35-3503). To each bottom-well was added 1.1 ml of the
regular growth medium containing 10% FBS. After 6 or
19-20 hours, cells migrating to bottom wells were trypsi-
nized, concentrated by centrifugation, and counted with
a haemacytometer. The experiments were repeated
three times and means and standard deviations of tripli-
cate values were calculated.
Cell invasiveness Assay
A cell invasiveness assay was carried out according to a
published method [19,20] with minor modifications
[8,9]. All procedures were similar to the cell motility
assay except before seeding cells to top wells, the porous
polycarbonate membrane (with a pore size of 12 μm) at
the bottom of each top well was coated with 50 μgo f
diluted Matrigel (growth factors-reduced and phenol-red
free grade, BD Biosciences Cat #354237 or Collaborative
Research Cat # 40234C). After 6 hours, cells migrating
to the bottom well were processed and counted. Alter-
natively, the porous polycarbonate membrane (with a
pore size of 8 μm) at the bottom of each top well was
coated with 150 μg of the diluted Matrigel. After 24
hours, cells migrating to the bottom well were processed
and counted. Means and standard deviations of triplicate
or six repeated values were calculated.
Anchorage-independent colony formation in soft agar
The published procedures [21] were followed with slight
modifications. 0.95 ml of 0.7% Noble agar was added to
each well (a diameter of 2.2 cm and a surface area of
3.8 cm
2) of a 12-well plate to form an agar plug. 1 × 10
4
MCF7 clones/cells in 0.9 ml of medium were mixed
with 0.1 ml of 3% Noble agar and seeded onto the agar
plug in each well and kept in a humidified 37 C
incubator. The number of colonies (20-50 cells per col-
ony) was counted after 14 days.
3D basement membrane culture assay
The published procedures of a 3D embedded basement
membrane culture assay [22] were followed with slight
modifications. Eight-chambered RS glass slides (Fisher
Cat #12-565-8, Nunc Lab-TekII chamber slide system,
Mfr #154534, 0.2-0.5 ml, 0.7-0.8 cm
2)w e r ep r e - c h i l l e d ,
coated with 30-40 μl of Cultrex (Matrigel prepared from
EHS, phenol red-free, growth factor-reduced, Cat #3433-
005-01 (5 ml), lot # 17307L8-S, Trevigen) per well to
form a thin layer and left to solidify for more than
30 min (and up to 3 hours) at 37°C in a humidified CO2
incubator. 0.15 ml of a cell suspension (5.3 × 10
5 cells/
m l )f r o mh e a l t h yM D A - M B - 2 3 1o rM D A - M B - 4 6 8
monolayer cultures was aliquot into each 1.5 ml micro-
centrifuge tube, to which was added 15 μg/ml of an anti-
huMETCAM/MUC18 antibody or the control isotype
antibody (chicken IgY), and incubated at room temp for
30 min. The medium was then carefully removed after
centrifugation in a pre-cooled Eppendorf Mini Spin
micro-centrifuge (115 × g for 4 min) and cells in each
tube were re-suspended in 0.075 ml of assay medium,
cooled on ice for 15 min, and mixed with an equal
volume of chilled 4% Matrigel in assay medium. The final
mixture (7.95 × 10
4 cells) was added to each chamber
already pre-coated with a thin layer of Matrigel and incu-
bated at 37°C for 30 min to 2 hours to allow EHS to gel.
0.2 ml of medium was added on top of the cells-EHS gel
and replaced every 2 days. The growth in the 3D base-
ment membrane culture assay was observed daily for 2 to
9 days and photographed with a SPOT digital camera
attached to an inverted Nikon microscope.
Determination of tumorigenesis of MCF7 clones/cells in
SCID mice
The guidelines of IACUC were strictly followed for the
animal studies. One day before injection hairs surround-
ing the left second and third nipples of 6-week-old
female SCID mice (Charles River) were removed with a
Veet hair removal gel cream (nouvelle formula, Reckitt
& Benckiser Inc, France). Ten mice were used for the
injection of each clone. A single cell suspension from
monolayer MCF7 cells of the pooled 2D clone (p18), the
2D-5 clone (p19) or the pooled 3D clone (p18) was pre-
pared, washed with PBS, re-suspended at 5 × 10
6 per ml
in cold 0.05 ml of EMEM without FBS, mixed with an
equal volume of 16 mg/ml of Cultrex, and subcuta-
neously injected with a gauge #28G1/2 needle under the
mammary fat pad of the third left nipple. After injec-
tion, the size of tumor was measured with a caliper
every week. Tumor volume was calculated by using the
formula V = π/6 (d1 × d2)
3/2 (mm)
3 [19]. At the
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from each mouse were excised, fixed in formaldehyde,
parafinized, and sectioned for histology and immunohis-
tochemical staining.
Western blot analysis
Cell and tumor lysates werep r e p a r e db ya d d i t i o no fa
Western blot lysis buffer that contained an anti-proteolysis
cocktail, as previously described [8,9]. The protein concen-
tration of each lysate was determined and verified after gel
electrophoresis and staining as described [8,9,18]. Western
blot analysis was followed as previously described
[2,8-10,18,23], except the electro-blotted nitrocellulose
membrane was incubated with a primary antibody for
16 hours at 4 C. Our chicken anti-huMETCAM/MUC18
IgY [2] (1/300 dilutions) was used as the primary antibody
to detect huMETCAM/MUC18 expression. Primary anti-
bodies for detecting the house-keeping gene products
actin and b-tubulin were a goat polyclonal antibody (SC-
1615, Santa Cruz Biotech) and a rabbit polyclonal antibody
(SC-9104, Santa Cruz Biotech), respectively. The second-
ary antibodies were rabbit anti-goat (AP106 A, Chemicon)
or goat anti-rabbit (AP132A, Chemicon), antibodies. The
color was developed by the addition of BCIP/NBT (S3771,
Promega). The image of a specific protein band corre-
sponding to METCAM/MUC18 on the membrane was
scanned with an Epson Scanner model 1260. The intensity
was quantitatively determined by NIH software program
Image J version 1.31.
Histology and immunohistochemistry (IHC) of tumor
sections
Paraffin-embedded tissue sections (5 μm) were used.
A tissue section of the subcutaneous tumor derived
from an LNCaP-expressing clone (LNS239) [3,10] was
used as a positive external control for IHC. Tissue sec-
tions were de-paraffinized, rehydrated with graded alco-
hol and PBS, and used for histological staining and IHC,
as previously described [9,10].
Statistical analysis of data
P values were obtained from statistical analyses by using
the Student’s t test (one-tailed distribution and type 1)
to compare data from experimental groups with the
control groups for all the figures except the Wilcox rank
sum test was also used for figure nine. Two sets of the
data were considered significantly different if the P
value was < 0.05.
Results
METCAM/MUC18 expression in four breast cancer cell
lines
We initiated the investigation by comparing the expres-
sion of METCAM/MUC18 in four human breast cancer
cell lines, MCF7, SK-BR-3, MDA-MB-231, and MDA-
MB-468 to cell lines whose levels of METCAM/MUC18
expression are well-characterized: the human melanoma
cell line SK-Mel-28, which highly expresses METCAM/
MUC18; the prostate cancer cell line DU145, which
moderately expresses METCAM/MUC18; and the pros-
tate cancer cell line LNCaP, which does not express
METCAM/MUC18.
Figure 1 shows that levels of METCAM/MUC18
expression in MCF7, SK-BR-3, MDA-MB-231, and
MDA-MB-468 were 0%, 5%, 16%, and 22% of that in
SK-Mel-28, respectively. METCAM/MUC18 expression
was consistently higher in cell lines established from
more malignant breast carcinomas, such as SK-BR-3
and MDA-MB-468, than cell lines from less malignant
breast carcinomas, such as MCF7 and MDA-MB-231.
We chose MCF7, MDA-MB 231, and MDA-MB-468 for
further studies.
METCAM/MUC18 expression in G418
R-clones derived from
MCF7 cells
Since MCF7 did not express any METCAM/MUC18, we
transfected METCAM/MUC18 cDNA into MCF7 cells
and obtained many G418
R-clones that expressed differ-
ent levels of METCAM/MUC18. Figure 2 shows the
results of pooled clones and three typical clones when
DEMRIE-C (Life Technology) was the transfecting
reagent. We found that both DEMRIE-C and FuGene
HD (Roche) were excellent transfecting reagents in gen-
erating a high percentage of highly expressing clones.
Figure 1 HuMETCAM/MUC18 expression in four human breast
cancer cell lines.5μg proteins of cell lysates were loaded in each
lane in Western blot analysis to determine the level of METCAM/
MUC18 in various cell lines. Cell lysates from a human melanoma
cell line, SK-Mel-18, and a human prostate cancer cell line, DU 145,
were used as positive controls (lanes 1-2), and that from a human
prostate cancer cell line, LNCaP, as a negative control (lane 3).
METCAM/MUC18 expression in cell lysates from four human breast
cancer cell lines, MCF7, SK-BR-3, MDA-MB-231, and MDA-MB-468,
were determined, as shown in lanes 4 to 7. The number under lane
indicates the relative level of METCAMMUC18 of each cell line,
assuming that in SK-Mel-28 as 100%. b-tubulin was used as the
loading control.
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and invasiveness of MCF7 cells
We used the pooled clones for experiments to eliminate
possible effects of individual clonal variations on the
results. Figure 3 shows the motility of MCF7 clones
6 hours after seeding the cells and Figure 4 after
19 hours. The results at 6 hours were similar to those at
19 hours, but the data were statistically better at
19 hours. Figure 3 shows that 6 hours after seeding
the cells the METCAM/MUC18 expressing clone had a
2-fold higher motility than the vector-control clone.
Figure 4 shows that 19 hours after seeding the cells the
METCAM/MUC18 expressing clone had a 3-fold higher
motility than the vector-control clone. Both Figures 3
and 4 show that the motility of the METCAM/MUC18-
expressing clone was significantly reduced in the pre-
sence of an anti-huMETCAM/MUC18 antibody, but not
the vector clone.
Figure 5 shows the invasiveness of MCF7 clones
6 hours after seeding the cells and Figure 6 after
24 hours. The results at 6 hours were similar to those at
24 hours, but the data were statistically better at
24 hours. Figure 5 shows that 6 hours after seeding the
cells (by coating with 50 μg of Matrigel and using a pore
size of 12 μm) the METCAM/MUC18 expressing clone
had a somewhat higher invasiveness than the vector-con-
trol clone. Figure 6 shows that 24 hours after seeding the
cells (by coating with 150 μg of Matrigel and using a pore
size of 8 μm) the METCAM/MUC18 expressing clone
had a significantly 2.6-fold higher invasiveness than the
vector control clone. Both Figures 5 and 6 show that the
invasiveness of the METCAM/MUC18-expressing clone
was significantly reduced in the presence of an anti-
huMETCAM/MUC18 antibody, but not the vector clone.
Taken together, we conclude that METCAM/MUC18
expression increased both the motility and invasiveness
Figure 2 HuMETCAM/MUC18 expression in various G418
R
clones of MCF7 cells.5μg proteins of each lysate were loaded in
each lane except lane 4, in which 10 μg protein were loaded in
Western blot analysis was used to determine the expression of
METCAM/MUC18 in various clones/cell lines. Cell lysate from a
human melanoma cell line, SK-Mel-18, was used as a positive
control (lane 1) and that from the parental human breast cancer cell
line MCF7 as a negative control (lane 2). METCAM/MUC18
expressions in cell lysates from five different MCF7 G418
R clones
(pooled 2D, pooled 3D, 2D1, 2D5, and 3D2) are shown in lanes 3-8.
The number under lane indicates the relative level of
METCAMMUC18 of each clone, assuming that in SK-Mel-28 as 100%.
b-tubulin was used as the loading control.
Figure 3 Effect of huMETCAM/MUC18 expression on in vitro
motility of MCF7 cells (6 hours). The motility of the pooled 2D
and 3D clones of MCF7 was determined 6 hours after seeding the
cells as described in “Materials and Methods” by using a pore size of
8 μm. 7.5 to 15 μg/ml of the anti-huMCAM/MUC18 antibody (open
columns) or the isotype control antibody (chicken IgY) (filled
columns) was added to block the motility of these clones. Means
and standard deviations of triplicate values of the test are shown.
Figure 4 Effect of huMETCAM/MUC18 expression on in vitro
motility of MCF7 cells (19 hours). The motility of the pooled 2D
and 3D clones of MCF7 was determined 19 hours after seeding the
cells as described in “Materials and Methods” by using a pore size of
8 μm. 7.5 to 15 μg/ml of the anti-huMCAM/MUC18 antibody (open
columns) or the isotype control antibody (chicken IgY) (filled
columns) was added to block the motility of these clones. Means
and standard deviations of triplicate values of the test are shown.
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expression of METCAM/MUC18.
METCAM/MUC18 expression increased in vitro anchorage-
independent colony formation of MCF7 cells in soft agar
Anchorage-independent colony formation in soft agar
has been successfully used to assess the tumorigenicity
of cancer cells in vitro, which has been positively corre-
lated to in vivo tumorigenicity in animal models [21].
Figure 7 shows quantitative results that the METCAM/
MUC18 expressing clone (the pooled 2D clone) had a
10-fold higher ability to form anchorage-independent
colonies than the vector-control clone (the pooled 3D
clone). We conclude that METCAM/MUC18 expression
increased the ability of MCF7 cells in forming ancho-
rage-independent colonies (in vitro tumorigenesis).
Effect of METCAM/MUC18 expression on in vivo tumor-
take and tumorigenicity of MCF7 clones/cells
In general, MCF7 cells manifest excellent tumorigenicity
in athymic nude mice if the cells are co-injected with
Matrigel and the mice are supplemented with estrogen
pellets [24]. SCID mice were used for the present stu-
dies with the aim of repeating the results of Shih et al.,
who did not implant mice with estrogen pellets [11].
Though we found that tumors were palpable, tumor
growth from both the pooled 2D and 3D clones in
SCID mice was poor in these immunodeficient mice
that were not supplemented with estrogen.
Figure 8 shows that the METCAM/MUC18-expressing
pooled 2D clone, which expressed high levels of MET-
CAM/MUC18, had a 30% tumor-take. Surprisingly, the
METCAM/MUC18-expressing 2D5 clone, which
expressed low levels of METCAM/MUC18, did not have
any tumor-take. In addition, the vector control clone had
a 10% tumor take, which was also unexpected. Figure 9
showed that the tumors of METCAM/MUC18-
Figure 5 Effect of huMETCAM/MUC18 expression on in vitro
invasiveness of MCF7 cells (6 hours). The invasiveness of the
pooled 2D and 3D clones of MCF7 was determined 6 hours after
seeding the cells as described in “Materials and Methods”. Since
MCF7 clones exhibits a property of very low invasiveness, to
observe more cells migrating to the bottom wells 6 hours after
seeding in the invasiveness assay the bottom membrane of the top
well was coated with 50 μg of Matrigel and a membrane with a
pore size of 12 μm used [20]. 7.5 to 15 μg/ml of the anti-huMCAM/
MUC18 antibody (open columns) or the isotype control antibody
(chicken IgY) (filled columns) was added to block the invasiveness
of these clones. Means and standard deviations of triplicate values
of the test are shown.
Figure 6 Effect of huMETCAM/MUC18 expression on in vitro
invasiveness of MCF7 cells (24 hours). The invasiveness of the
pooled 2D and 3D clones of MCF7 was determined as 24 hours
after seeding the cells described in “Materials and Methods” by
coating with 150 μg of Matrigel and using a pore size of 8 μm. 7.5
to 15 μg/ml of the anti-huMCAM/MUC18 antibody (open columns)
or the isotype control antibody (chicken IgY) (filled columns) was
added to block the invasiveness of these clones. Means and
standard deviations of six repeated values of the test are shown.
Figure 7 Effect of huMETCAM/MUC18 expression on MCF7
cells in the formation of anchorage-independent colonies.
Abilities of MCF7 clones to form anchorage-independent colonies
were determined by the soft agar colony formation assay as
described in “Materials and Methods”. Quantitative results of the
formation of anchorage-independent colonies by the pooled 2D
clone, which was transfected with the huMETCAM/MUC18 cDNA
gene, and the pooled 3D clone, which was transfected with the
empty vector, are shown. The mean values and standard deviations
from the colony numbers in at least four wells are shown.
Zeng et al. BMC Cancer 2011, 11:113
http://www.biomedcentral.com/1471-2407/11/113
Page 6 of 13expressing pooled 2D clone appeared about 6 days earlier
than the vector control pooled 3D clone.
The mean final tumor volume of the three tumor-
bearing mice injected with the pooled 2D clone was
~4.6 ± 3.1 mm
3. The final tumor volume of the single
tumor-bearing mouse injected with the vector clone was
~14.1 mm
3.
Histology and IHC of MCF7 tumors
Figure 10 shows the histology of the MCF7 tumors from
the pooled 2D and 3D clones (Panels A-D). As shown in
Panels A-D (Figure 10), only micro-lesions of tumors
were observed, as if the tumors were in dormancy. Fig-
u r e1 0a l s os h o w st h eI H Co ft h e s et u m o rs e c t i o n st h a t
METCAM/MUC18-specific antigens were expressed in
the tumors of the 2D clone (Panels F&G), but not in
adjacent tumor sections, in which the control isotype
antibody (chicken IgY) was added (Panels J&K). In con-
trast, METCAM/MUC18-specific antigens were poorly
expressed in the tumor of the 3D clone (Panel H), simi-
lar to the adjacent tumor section, in which the control
isotype antibody (chicken IgY) was added (Panel L).
IHC results of the tumor sections were consistent with
the in vitro METCAM/MUC18 expression levels in both
the pooled 2D and 3D clones (shown in Figure 2), sug-
gesting that the tumors were from the injected MCF7
clones/cells.
Effect of METCAM/MUC18 expression on in vitro motility
and invasiveness of MDA-MB-231 and MDA-MB-468 cells
Figure 11 shows the motility of both MDA-MB-231 and
MDA-MB-468 cells 6 hours after seeding the cells and
Figure 12 after 20 hours. The results at 6 hours were
similar to those at 20 hours, but the data were statisti-
cally better at 20 hours. At both time points MDA-MB-
231 cells had an 11-fold higher level of motility than the
METCAM/MUC18-expressing clones of MCF7 cells
(Figures 11 and 12 versus Figures 3 and 4). As also
shown in Figures 11 and 12, MDA-MB-231 cells consis-
tently had a significantly higher motility than
MDA-MB-468 cells. At 6 hours after seeding the cells
MDA-MB-468 cells exhibited motility similar to the
METCAM/MUC18-expressing clones of MCF7 cells
(Figure 11 versus Figure 3), but at 20 hours after seeding
the cells MDA-MB-468 cells had a significant 8-fold
higher level of motility than the METCAM/MUC18-
expressing clones of MCF7 cells (Figure 12 versus Fig-
ure 4). At both time points, MDA-MB-468 had a signifi-
cantly higher level of motility than the vector control
clone of MCF7 cells (Figures 11 and 12 versus Figures 3
and 4). As also shown in Figure 11 and 12, the motility
of both these cell lines was significantly reduced in the
presence of an anti-huMETCAM/MUC18 antibody.
Figure 13 shows the invasiveness of both MDA-MB-
231 and MDA-MB-468 cells 6 hours after seeding the
cells and Figure 14 after 24 hours. The results at 6
hours were similar to those at 24 hours, but the data
were statistically better at 24 hours. At both time points
MDA-MB-231 cells had a 2.5 to 3-fold higher level of
invasiveness than the METCAM/MUC18-expressing
clones of MCF7 cells (Figures 13 and 14 versus Figures
5 and 6). As also shown in Figures 13 and 14, MDA-
MB-231 cells consistently had a higher invasiveness
than MDA-MB-468 cells. At 6 hours MDA-MB-468
cells had a lower invasiveness than the METCAM/
Figure 8 Effect of huMETCAM/MUC18 expression on the
tumor-take of MCF7 cells in SCID mice. Tumor-take was the
number of mice that bore tumor after injection of the cells and was
carried out in female SCID mice which were injected with MCF7
cells from the huMETCAM/MUC18-expressing pooled 2D clone and
a clone 2D5 and from an empty vector control pooled 3D clone.
Figure 9 Effect of huMETCAM/MUC18 expression on the
tumorigenicity of MCF7 cells in SCID mice. Tumorigenicity was
determined as described in “Materials and Methods” and is shown
as the mean tumor volumes at different time from ten SCID mice
for each of the three clones, as described in Figure 8.
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Page 7 of 13MUC18-expressing clones of MCF7 cells (Figure 13 ver-
sus Figure 5). At 24 hours MDA-MB-468 cells had inva-
siveness similar to the METCAM/MUC18-expressing
clones of MCF7 cells (Figure 14 versus Figure 6). At 6
hours MDA-MB-468 cells had invasiveness similar to
the vector control clone of MCF7 (Figure 13 versus Fig-
ure 5), but at 24 hours MDA-MB-468 cells had a 2-fold
higher level of invasiveness than the vector control
clone of MCF7 (Figure 14 versus Figure 6). As also
shown in Figures 13 and 14, the invasiveness of both
these cell lines was significantly reduced in the presence
of an anti-METCAM/MUC18 antibody.
Taken together, we conclude that the endogenous
expression of METCAM/MUC18 increased both the
motility and invasiveness of MDA-MB-231 and MDA-
MB-468 cells.
Effect of METCAM/MUC18 expression on a 3D basement
membrane culture assay of the MDA-MB-231 and MDA-
MB-468 cells
The 3D basement membrane culture has been demon-
strated to mimic the in vivo growth of normal breast
epithelial cells and tumor cells, supporting the former in
an organized growth and proper differentiation and the
latter in a disorganized growth and manifesting invasive-
ness [22,25]. Figure 15 shows that both MDA-MB-231
and MDA-MB-468 could establish a disorganized
growth in a 3D embedded basement membrane culture
Figure 10 Histology and immunohistochemistry (IHC) of MCF7 tumors grown in SCID mice. Histology of tumors derived from pooled 2D
and 3D clones are shown in Panels A-D. IHC of tumors from pooled 2D and 3D clones are shown in Panels F-H and J-L. Tumors from the clone
LNS239 of LNCaP cells subcutaneously injected to nude mice [3,10,32] was used as a positive control for IHC (panels E & I). The anti-human
METCAM/MUC18 antibody (+Ab) was added to IHC in Panels E-H. Arrows show the positively stained cells by the anti-human METCAM/MUC18
antibody in the tumors derived from METCAM/MUC18-expressing MCF7 clones/cells (the pooled 2D clone). The control isotype antibody (CIgY)
was added to the IHC in Panels I-L, as negative controls. Tumor sections from the tumors derived from the vector control 3D clone (Panels H&L)
were also used as negative controls.
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disorganized growths were destroyed in the presence of
an anti-huMETCAM/MUC18 antibody (Panels C and
F), suggesting the expression of METCAM/MUC18 is
required for them to establish a disorganized growth in
a 3D basement membrane culture assay.
Discussion
We have shown that the expression of METCAM/
MUC18 significantly increased the in vitro motility,
invasiveness, and tumorigenesis of three breast cancer
cell lines: MCF7, MDA-MB-231, and MDA-MB-468.
The positive effect of METCAM/MUC18 expression on
the in vitro motility and invasiveness of these clones/cell
lines was due to the direct effect of METCAM/MUC18,
Figure 11 Effect of huMETCAM/MUC18 expression on in vitro
motility of MDA-MB-231 and MDA-MB-468 cell lines (6 hours).
The motility of MDA-MB-231 and MDA-MB-468 cells was
determined 6 hours after seeding the cells as described in “Materials
and Methods” by using a pore size of 8 μm. 7.5 to 15 μg/ml of the
anti-huMCAM/MUC18 antibody (open columns) or the isotype
control antibody (chicken IgY) (filled columns) was added to block
the motility of these clones. Means and standard deviations of
triplicate values of the test are shown.
Figure 12 Effect of huMETCAM/MUC18 expression on in vitro
motility of MDA-MB-231 and MDA-MB-468 cell lines (20 hours).
The motility of MDA-MB-231 and MDA-MB-468 cells was
determined 20 hours after seeding the cells as described in
“Materials and Methods” by using a pore size of 8 μm. 7.5 to 15 μg/
ml of the anti-huMCAM/MUC18 antibody (open columns) or the
isotype control antibody (chicken IgY) (filled columns) was added to
block the motility of these clones. Means and standard deviations of
triplicate values of the test are shown.
Figure 13 Effect of huMETCAM/MUC18 expression on in vitro
invasiveness of MDA-MB-231 and MDA-MB-468 cell lines
(6 hours). The invasiveness of MDA-MB-231 and MDA-MB-468 cells
was determined 6 hours after seeding the cells as described in
“Materials and Methods”. Similar to Figure 5, in order to observe
more cells migrating to the bottom wells 6 hours after seeding in
the invasiveness assay the bottom membrane of the top well was
coated with 50 μg of Matrigel and a membrane with a pore size of
12 μm used [20]. 7.5 to 15 μg/ml of the anti-huMCAM/MUC18
antibody (open columns) or the isotype control antibody (chicken
IgY) (filled columns) was added to block the invasiveness of these
clones. Means and standard deviations of triplicate values of the test
are shown.
Figure 14 Effect of huMETCAM/MUC18 expression on in vitro
invasiveness of MDA-MB-231 and MDA-MB-468 cell lines
(24 hours). The invasiveness of MDA-MB-231 and MDA-MB-468 cells
was determined 24 hours after seeding the cells as described in
“Materials and Methods” by coating with 150 μg of Matrigel and
using a pore size of 8 μm. 7.5 to 15 μg/ml of the anti-huMCAM/
MUC18 antibody (open columns) or the isotype control antibody
(chicken IgY) (filled columns) was added to block the invasiveness
of these clones. Means and standard deviations of triplicate values
of the test are shown.
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CAM/MUC18-expressing clones/cell lines were signifi-
cantly reduced in the presence of an anti-METCAM/
MUC18 antibody. This also was not due to the higher
proliferation rate of the METCAM/MUC18-expressing
c l o n e s / c e l ll i n e ss i n c ew eh a v ep r e v i o u s l ys h o w nt h a t
increased expression of METCAM/MUC18 in mela-
noma and prostate cancer cells did not confer a higher
in vitro proliferation (growth) rate of these cells and a
similar effect was also found in breast cancer cells (data
not shown) [8,9]. Furthermore, the in vitro doubling
time of these cells was longer than the duration of the
experiments, especially at the time point of 6 hours. In
addition, the cells in the top well were in a serum-free
medium, in which they were still alive, but their growth
was arrested until they reached to the bottom wells.
Taken together, these findings support the notion that
METCAM/MUC18 promotes the progression of breast
cancer cells. Since MCF7 clones had a lower motility
and invasiveness than MDA-MB-231 and MDA-MB-468
cell lines, this may reflect the fact that MCF7 cells exhi-
bit an epithelial morphology, whereas the latter two cell
lines a mesenchymal (spindle shape) morphology.
To resolve the contradictory conclusions of the role of
METCAM/MUC18 in the progression of breast cancer,
we re-investigated effects of METCAM/MUC18 expres-
sion on in vivo tumorigenesis of MCF7 cells. Using the
data from Shih et al. [11] we found that if the tumor
volume was calculated using our ellipsoid equation [19],
the mean final tumor volume from their vector control
clone would have been ~27 ± 7.5 mm
3,w h i c hw a s
about two times larger than our corresponding control
clone (14.1 mm
3) ,a n dt h a tf r o mt h e i rM E T C A M -
expressing clone would have been ~3.5 ± 2.6 mm
3,
which was similar to our corresponding clone (~4.6 ±
3.1 mm
3). The results in Shih et al. and this report are
both consistent with the results of all previously pub-
lished work by other groups indicating that without
Figure 15 Effect of huMETCAM/MUC18 expression on a disorganized growth of MDA-MB-231 and MDA-MB-468 cell lines in 3D
basement membrane culture assay. The embedded 3D basement membrane culture assay was carried out as described in “Materials and
Methods”. Panels A and D, in which no antibody was added, show a disorganized growth of both MDA-MB-231 and MDA-MB-468 cells in 3D
culture assay, respectively. Panels B and E, in which the control isotype antibody (Chicken IgY) was added, show results similar to Panels A and
D. Panels C and F show that the disorganized growth of both MDA-MB-231 and MDA-MB-468 cells in 3D culture assay was destroyed in the
presence of 15 μg/ml of anti-huMETCAM/MUC18 antibody, respectively.
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Page 10 of 13estrogen pellets, the in vivo tumorigenesis of MCF7 cells
in immuno-deficient mice should be very poor [24], sug-
gesting that in the absence of estrogen the tumor cells
may remain in a dormant state. It is unclear why Shih
et al. observed a two-fold larger tumor volume from the
vector control clone compared to ours. The different
results between the two groups may be attributed to the
presence of fetal bovine serum, which was the main dif-
ference between injection protocols. Fetal bovine serum
may partially provide a growth advantage for the vector
control clone, but not to the METCAM/MUC18-expres-
sing clone, to proliferate without the need of supple-
mental estrogen [11].
In addition, Shih et al. found that METCAM/MUC18
expression suppressed the in vivo tumorigenesis of
MCF7 cells [11]. In contrast, using a more standard
method of co-injection of the MCF7 cells with growth-
factor reduced Matrigel (without fetal bovine serum)
[19,24], we observed a positive effect of METCAM/
M U C 1 8e x p r e s s i o no nt h et u m o rg r o w t ho fM C F 7
cells in SCID mice. This conclusion was drawn,
because the statistical significance of the final single
tumor volume from one mouse out of ten from the
vector control clone was minimal (though it appeared
to be higher than the mean final tumor volume of the
three tumors from the METCAM/MUC18 expressing
pooled 2D clone). Furthermore, all the mice injected
with the cells of the 2D5 clone, which expressed a low
level of METCAM/MUC18 and thus was almost like
the vector control, did not bear any tumor. Moreover,
we found that METCAM/MUC18 expression increased
tumor-take and showed a slightly earlier appearance of
tumors, though the tumor growth was very poor. We
are unable to compare the results of tumor-take from
the work of Shih et al., since they did not show this
result. Thus, the tumor suppression effect of MET-
CAM/MUC18 in animal studies by Shih et al. [11]
could not be reproduced. It is possible that the tumor
suppressive effect of METCAM/MUC18 observed by
Shih et al. was due to the differential effect of fetal
bovine serum.
Another interesting finding (Figure 8) is that the high
expression pooled 2D clone had a 30% tumor-take
whereas the low expression 2D5 clone had no tumor-
take. This suggests that the dosage of METCAM/
MUC18 expressed in MCF7 cells may affect in vivo
tumorigenesis. However, this requires further extensive
investigations.
Taken together, we conclude that METCAM/
MUC18 plays a positive role in the progression of
three breast cancer cell lines, MCF7, MDA-MB-231,
and MDA-MB-468. Consistent with this notion, we
also observed a similarly positive effect of the
METCAM/MUC18 expression on in vitro cellular
behaviors of another luminal-like cell line, SK-BR-3,
and an even more dramatic positive effect of the pro-
tein on in vivo t u m o r i g e n e s i so ft h i sc e l ll i n ei nn u d e
mice [26,27].
T h em e c h a n i s m sb yw h i c hh u M E T C A M / M U C 1 8
expression affects the tumorigenesis of breast cancer
cells are poorly understood. Using knowledge derived
from tumorigenesis of other tumors [28] and functions
of huMETCAM/MUC18 in endothelial cells and mela-
noma [3,4,15,29-31], huMETCAM/MUC18 expression
may increase tumorigenesis by cross-talk with many
signaling pathways that affect survival, proliferation,
and angiogenesis of tumor cells [3,4]. We therefore
p r e d i c tt h a te n f o r c e de x p r e s s i o no fh u M E T C A M /
MUC18 may increase tumorigenesis by affecting its
key downstream effectors, such as decreasing apoptosis
and increasing survival and proliferation of the cells.
This notion has been supported by our recent observa-
tions that METCAM/MUC18 promotes progression of
prostate cancer cells by increasing proliferative indexes
(KI67 and PCNA), a survival signaling index (P-AKT/
AKT ratio), and pro-angiogenic indexes (VEGF,
VEGFR2, and CD31); however, it did not affect apop-
tosis, which is different from its role in melanoma
[32]. Since METCAM/MUC18 promotes both the pro-
gression of prostate cancer and breast cancer cells, we
anticipate that up-regulation of METCAM/MUC18
may increase expression of similar downstream key
parameters during the progression of breast cancer
cells. This notion is supported by our recent unpub-
lished results that VEGFR2 levels in METCAM/
MUC18-expressing human breast cancer SK-BR-3
tumors were at least two-fold higher than in the vector
control SK-BR-3 tumors [26,27].
With regard to the regulation of expression of the
METCAM/MUC18 gene in various tumor cells, the
METCAM/MUC18 gene is up-regulated at the tran-
scriptional level by PKA via CREB-binding site in the
promoter [33] and down-regulated by the transcription
factor AP-2 in a human melanoma system [34]. Similar
transcriptional regulation of the METCAM/MUC18
gene in breast cancer cells may be used; however, this
notion requires future investigation.
Conclusions
The over-expression of METCAM/MUC18 is likely to
promote the tumor progression of luminal-like and
basal-like human breast cancer cells. The results of Shih
et al. [11], which suggested a tumor-suppressive effect
of METCAM/MUC18, were unable to be reproduced
using standard methods of animal studies. The positive
role of METCAM/MCU18 in the progression of breast
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Page 11 of 13cancer is very likely to be similar to that in melanoma
and prostate cancer [3,6-10,32]; thus METCAM/MUC18
may be a potential therapeutic target for an alternative
treatment of breast cancer [35,36].
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